Application of rosa roxburghii or rosa roxburghii extract in preparation of drug or health care product for preventing and treating pulmonary fibrosis

A technology for pulmonary fibrosis and health products, applied in food ingredients containing natural extracts, medical preparations containing active ingredients, applications, etc., can solve problems such as increased risk of respiratory failure, decreased immunity, liver and kidney damage, etc. Achieve significant clinical and social significance, good curative effect, and low toxicity

Inactive Publication Date: 2020-03-31
SICHUAN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional treatment is mainly to suppress inflammation, but long-term use of glucocorticoids, immunosuppressants, cyclophosphamide and other drugs can cause liver and kidney dam

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rosa roxburghii or rosa roxburghii extract in preparation of drug or health care product for preventing and treating pulmonary fibrosis
  • Application of rosa roxburghii or rosa roxburghii extract in preparation of drug or health care product for preventing and treating pulmonary fibrosis
  • Application of rosa roxburghii or rosa roxburghii extract in preparation of drug or health care product for preventing and treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 In vitro cell experiment of Rosa roxburghii juice preventing and treating pulmonary fibrosis

[0033] The excessive proliferation of mouse embryonic fibroblasts (NIH3T3) and pancreatic cancer human alveolar basal epithelial cells (A549) can cause collagen deposition, therefore, inhibiting their proliferation can inhibit the expression and deposition of collagen.

[0034] In the process of pulmonary fibrosis, TGF-β is the main fibrosis factor, which can promote epithelial-mesenchymal transition (EMT) in vitro, inhibit the apoptosis of fibroblasts, and promote the production of reactive oxygen species; Studies have also shown that the massive release of TGF-β will accelerate the process of pulmonary fibrosis. After A549 is stimulated by TGF-β1, it will accelerate the process of epithelial-mesenchymal transition (EMT), and then accelerate the formation of pulmonary fibrosis. Therefore, inhibiting the transformation of EMT can reduce the formation of pulmonary fib...

Embodiment 2

[0048] Example 2 In vivo animal experiment of Rosa roxburghii juice preventing and treating bleomycin-induced pulmonary fibrosis

[0049] Bleomycin (BLM) is a drug against squamous cell carcinoma, but it can cause pulmonary fibrosis. After bronchial infusion of bleomycin, type Ⅰ alveolar epithelial cells secrete pro-inflammatory factors after inflammatory injury, the proliferation and differentiation of type Ⅱ epithelial cells can be observed on the second day, myofibroblasts are recruited, synthesize collagen and Cause extracellular matrix accumulation, resulting in tissue and interstitial fibrosis. This is consistent with the induction of diffuse pulmonary fibrosis or fibrotic alveolitis in humans, suggesting that bleomycin-induced injury may provide a suitable model for this disease of unknown etiology and pathogenic mechanism. Based on this, this experiment established a bleomycin-induced pulmonary fibrosis model (CNV) in C57BL / 6 mice, and evaluated the effect of Rosa rox...

Embodiment 3

[0065] Example 3 In vitro safety evaluation of Rosa roxburghii juice

[0066] 1. Cell Culture

[0067] Normal kidney cells (VREO) were cultured in DMEM high-glucose medium containing 10% FBS, and 100 U / mL of penicillin and streptomycin were required to be added during the culture and experiment, and cultured at 37°C, 5% CO 2 in the incubator.

[0068] 2. MTT method to detect the effect of roxburghii juice on the proliferation of normal kidney cells (VREO)

[0069] Select cells in good logarithmic growth state, inoculate a 96-well plate according to the cell growth rate, about 1500-2000 cells per well, 100 μL per well, at 37 ° C, 5% CO 2 Incubator cultivation. On the second day after inoculation, add 100 μL of thorn pear juice dilution prepared with fresh medium to each well to make the final concentration 0 μL / mL, 10 μL / mL, 20 μL / mL, 30 μL / mL, 40 μL / mL, 50 μL / mL, Set up 5 duplicate wells at the same concentration, at 37°C, 5% CO 2 After culturing in the incubator for 24, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention, which belongs to the field of drugs or health care products, relates to application of rosa roxburghii or rosa roxburghii extract in preparation of a drug or health care product for preventing and treating pulmonary fibrosis. The invention provides application of rosa roxburghii or rosa roxburghii extract in preparation of a drug or health care product for preventing and treating pulmonary fibrosis. The in-vitro and in-vivo experiments prove that the rosa roxburghii can play an exact role in treating pulmonary fibrosis; toxicity to normal kidney cells is low; and the safety is high. Therefore, the pulmonary fibrosis can be prevented and a drug or health care product with good curative effect, low toxicity and low price for patients with pulmonary fibrosis can be provided. The application of rosa roxburghii or rosa roxburghii extract in preparation of a drug or health care product for preventing and treating pulmonary fibrosis has the remarkable clinical and social significance.

Description

technical field [0001] The invention relates to the use of roxburghii or its extract in the preparation of medicines or health products for preventing and treating pulmonary fibrosis, belonging to the field of medicines or health products. Background technique [0002] Pulmonary fibrosis (Lung fibrosis) is a chronic, progressive lung injury or the result of lung disease to an advanced stage. Its pathological features are alveolitis, massive proliferation of fibroblasts, accumulation of extracellular matrix in the lung tissue accompanied by inflammatory damage, destruction of the alveolar structure, and abnormal repair of the damaged tissue leading to scar formation, which hinders the gas exchange between the lung and the outside world. Eventually respiratory failure and death result. The clinical symptoms of pulmonary fibrosis mainly include dyspnea, hypoxemia, and dry cough. With the deterioration of human living environment, pollution and other factors, the incidence of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/738A61P11/00A23L2/02A23L19/00A23L33/105A61K131/00
CPCA23L2/02A23V2002/00A61K36/738A61K2236/31A23L19/00A23L33/105A61P11/00A23V2200/314A23V2250/21
Inventor 阴文娅叶庭洪王礼群李沙李亚丽张倩钰
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap